抗程序性细胞死亡蛋白 1 皮肤毒性作用与晚期黑色素瘤患者结局的关联。
Association of Anti-Programmed Cell Death 1 Cutaneous Toxic Effects With Outcomes in Patients With Advanced Melanoma.
机构信息
Vanderbilt University School of Medicine, Nashville, Tennessee.
Department of Dermatology, Vanderbilt University Medical Center, Nashville, Tennessee.
出版信息
JAMA Oncol. 2019 Jun 1;5(6):906-908. doi: 10.1001/jamaoncol.2019.0046.
Abstract
This cohort study of patients with advanced melanoma treated with anti–programmed cell death 1 with or without ipilimumab assessed whether cutaneous toxic effects were associated with superior clinical outcomes.
摘要
本队列研究纳入了接受抗程序性死亡 1 治疗联合或不联合伊匹单抗治疗的晚期黑色素瘤患者，评估了皮肤毒性反应是否与更好的临床结局相关。
相似文献
1
Association of Anti-Programmed Cell Death 1 Cutaneous Toxic Effects With Outcomes in Patients With Advanced Melanoma.
JAMA Oncol. 2019 Jun 1;5(6):906-908. doi: 10.1001/jamaoncol.2019.0046.
2
Vitiligo under anti-programmed cell death-1 therapy is associated with increased survival in melanoma patients.
J Am Acad Dermatol. 2020 Mar;82(3):770-772. doi: 10.1016/j.jaad.2019.11.017. Epub 2019 Nov 14.
3
Adverse Reactions to Biologics: Melanoma (Ipilimumab, Nivolumab, Pembrolizumab).
Curr Probl Dermatol. 2018;53:82-92. doi: 10.1159/000478081. Epub 2017 Nov 7.
4
Cutaneous adverse effects during ipilimumab treatment for metastatic melanoma: a prospective study.
Eur J Dermatol. 2017 Jun 1;27(3):266-270. doi: 10.1684/ejd.2017.3023.
5
Cutaneous Eruption Secondary to Immunotherapy for Metastatic Melanoma Limited to Sites of Locoregional Melanoma Metastases: A Possible Variant of Locus Minoris Resistentiae.
JAMA Dermatol. 2018 Jul 1;154(7):846-847. doi: 10.1001/jamadermatol.2018.0654.
6
Lupus-like cutaneous reaction following pembrolizumab: An immune-related adverse event associated with anti-PD-1 therapy.
J Cutan Pathol. 2018 Jan;45(1):74-77. doi: 10.1111/cup.13059. Epub 2017 Nov 10.
7
Vitiligo-like lesions occurring in patients receiving anti-programmed cell death-1 therapies.
G Ital Dermatol Venereol. 2019 Aug;154(4):435-443. doi: 10.23736/S0392-0488.18.06254-5. Epub 2019 Jan 16.
8
Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial.
Lancet. 2014 Sep 20;384(9948):1109-17. doi: 10.1016/S0140-6736(14)60958-2. Epub 2014 Jul 15.
9
Granulomatous Reaction in a Patient With Metastatic Melanoma Treated With Ipilimumab: First Case Reported With Isolated Cutaneous Findings.
Actas Dermosifiliogr (Engl Ed). 2019 Jan-Feb;110(1):43-49. doi: 10.1016/j.ad.2017.11.021. Epub 2018 Oct 30.
10
Risk of dermatologic and mucosal adverse events associated with PD-1/PD-L1 inhibitors in cancer patients: A meta-analysis of randomized controlled trials.
Medicine (Baltimore). 2019 May;98(20):e15731. doi: 10.1097/MD.0000000000015731.
引用本文的文献
1
Vitiligo-like rash in a patient with lung cancer caused by sintilimab: A case report.
World J Clin Cases. 2025 May 16;13(14):101981. doi: 10.12998/wjcc.v13.i14.101981.
2
Immune checkpoint inhibitors: From friend to foe.
Toxicol Rep. 2025 Apr 24;14:102033. doi: 10.1016/j.toxrep.2025.102033. eCollection 2025 Jun.
3
Impact of steroid dose and timing on efficacy of combination PD-1/CTLA-4 blockade.
Oncoimmunology. 2025 Dec;14(1):2494433. doi: 10.1080/2162402X.2025.2494433. Epub 2025 Apr 18.
4
Association of Cutaneous Immune-related Adverse Events with Overall Survival and Progression-free Survival in Oncology Patients Receiving Immune Checkpoint Inhibitors: A Prospective Study of 189 Patients in a Spanish Tertiary Care Hospital.
Acta Derm Venereol. 2025 Jan 3;105:adv42023. doi: 10.2340/actadv.v105.42023.
5
First cycle toxicity and survival in patients with rare cancers treated with checkpoint inhibitors.
J Natl Cancer Inst. 2025 Apr 1;117(4):692-700. doi: 10.1093/jnci/djae297.
6
The many faces of autoimmune-mediated melanocyte destruction in melanoma.
Front Immunol. 2024 Oct 3;15:1417273. doi: 10.3389/fimmu.2024.1417273. eCollection 2024.
7
Evaluation of the association between predictive factors and the development of immune-related adverse events and prognostic factors for chemoimmunotherapy in patients with non-small cell lung cancer: A multicenter retrospective study.
Cancer Med. 2024 Aug;13(15):e70080. doi: 10.1002/cam4.70080.
8
Prophylactic IL-23 blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy.
J Immunother Cancer. 2024 Jul 31;12(7):e009345. doi: 10.1136/jitc-2024-009345.
9
Efficacy of adjuvant immune checkpoint inhibitors pembrolizumab or nivolumab in melanoma patients ≥ 75 years: results of a real-world cohort including 456 patients.
Cancer Immunol Immunother. 2024 Jul 5;73(9):185. doi: 10.1007/s00262-024-03750-1.
10
Efficacy and predictors of immune checkpoint inhibitors in patients with gallbladder cancer.
Cancer Sci. 2024 Jun;115(6):1979-1988. doi: 10.1111/cas.16142. Epub 2024 Mar 15.
本文引用的文献
1
Resident Memory and Recirculating Memory T Cells Cooperate to Maintain Disease in a Mouse Model of Vitiligo.
J Invest Dermatol. 2019 Apr;139(4):769-778. doi: 10.1016/j.jid.2018.10.032. Epub 2018 Nov 10.
2
Immune Checkpoint Inhibitor Toxicity in 2018.
JAMA. 2018 Oct 23;320(16):1702-1703. doi: 10.1001/jama.2018.13995.
3
High-dose glucocorticoids for the treatment of ipilimumab-induced hypophysitis is associated with reduced survival in patients with melanoma.
Cancer. 2018 Sep 15;124(18):3706-3714. doi: 10.1002/cncr.31629. Epub 2018 Jul 5.
4
Pruritus Associated with Targeted Anticancer Therapies and Their Management.
Dermatol Clin. 2018 Jul;36(3):315-324. doi: 10.1016/j.det.2018.02.010.
5
Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma.
J Clin Oncol. 2017 Mar;35(7):785-792. doi: 10.1200/JCO.2015.66.1389. Epub 2016 Nov 14.
6
Association of Vitiligo With Tumor Response in Patients With Metastatic Melanoma Treated With Pembrolizumab.
JAMA Dermatol. 2016 Jan;152(1):45-51. doi: 10.1001/jamadermatol.2015.2707.
Zotero 插件